Glatt Pharmaceutical Services and Aprecia have teamed up to accelerate and expand the use of Glatt’s multiparticulate technologies through Aprecia’s 3DP manufacturing. This effort will focus on overcoming oral pharmaceutical design challenges presented by conventional manufacturing. Leveraging Aprecia’s ZipDose technology, the collaboration will initially target existing products for modified release 505(b)(2) brand line extensions as well as new chemical entities (NCE) through...